Saturday, July 11, 2026

pharma · Myelodysplastic Syndromes (MDS) · Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)

Taiho Pharma Canada

Taiho Pharma Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Sol

2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA HQ
2017 Founded
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
2010 Winston Park Drive, Suite 503, Oakville, Ontario L6H 5R7, CA
Founded
2017
Employees
13
Programs
16
Drugs
30
Patents
0
Clinical program

TAS-120

Phase 2 · small molecule · Advanced Cholangiocarcinoma

TAS-120 for Advanced Cholangiocarcinoma is a Phase 2 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).

Internal code TAS-120-205

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Taiho Pharma Netherlands B.V.
Phase
Phase 2
Modality
small_molecule
Indication
Advanced Cholangiocarcinoma
Status
active
Trials
1

Clinical trials